Open access

Dipeptidyl Peptidase-IV and Related Proteases in Brain Tumors

Written By

Petr Busek and Aleksi Sedo

Submitted: 28 April 2012 Published: 27 February 2013

DOI: 10.5772/53888

From the Edited Volume

Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications

Edited by Terry Lichtor

Chapter metrics overview

2,605 Chapter Downloads

View Full Metrics

1. Introduction

Malignant gliomas rank among the most aggressive human tumors. The hallmarks of these tumors include a highly infiltrative behavior, aberrant cell proliferation and apoptosis, increased angiogenesis and intratumoral as well as systemic immunosuppression [1, 2]. Proteases localized on the cell-surface or released extracellularly may significantly contribute to these characteristics by mediating the breakdown of the components of the extracellular matrix (ECM), liberating growth factors sequestered by binding to the ECM, regulating the activity of paracrine mediators and shedding of cell-surface proteins [3]. There is substantial evidence for the role of matrix metalloproteinases (MMP), the serine protease urokinase-type plasminogen activator (uPA) and the cysteine protease cathepsin B in glioma invasion [4], angiogenesis [5] and proliferation. In addition, expression of proteases such as cathepsin D, uPA or MMP-9 in the clinical material may predict patient prognosis [6-8]. Nevertheless, the role of several proteases including the canonical dipeptidyl peptidase-IV (DPP-IV) and related proteases in glioma progression remains largely unknown with only few studies using synthetic inhibitors or genetic manipulation to determine their function. In this chapter, we review the basic characteristics of DPP-IV and related proteases, focus on their functional role in the transformed as well as stromal cells, and discuss the implications for the biology of human gliomas.

1.1. "Dipeptidyl peptidase-IV activity and/or structure homologous" (DASH) molecules

Historically, dipeptidyl peptidase-IV (DPP-IV, EC, identical with the lymphocyte differentiation antigen CD26) was described by Hopsu-Havu and Glenner [9] in liver homogenates on the basis of its unique hydrolytic activity cleaving N-terminal dipeptides from synthetic chromogenic substrates with the proline residue in the penultimate position. The presence of similar enzymatic activity was observed in body fluids soon after that [10, 11]. At that time, DPP-IV was hypothesized to participate on the turnover of the regulatory as well as structural proteins bearing the consensus cleavage sequence. However, the speculations about its particular biological roles awaited experimental confirmation. Subsequently, multiple authors noted substantial heterogeneity of molecular forms that possessed strikingly similar enzymatic activity but differed in molecular weight, isoelectric point and subcellular localization [12]. It took several years to identify and characterize other "DPP-IV-like" molecules, individual gene products, exhibiting various degree of structural homology with the canonical DPP-IV. These comprise the intracellularly localized DPP8 and DPP9 (both still assigned under the same EC [13, 14], the plasma membrane fibroblast activation protein-alpha/seprase (FAP, EC 3.4.21.B28) [15] as well as the DPP-IV sequentially dissimilar intracellular DPP-II (quiescent cell proline dipeptidase, DPP7, EC[16]. Besides, highly structurally similar but hydrolytically inactive DPP6 and DPP10 were discovered later [17]. Recently, all these molecular species are by some authors referred to as the "Dipeptidyl peptidase-IV activity/and or structure homologous" (DASH) molecules [18-24]. Formerly, Glutamate carboxypeptidase II (GCPII, N-acetyl-L-aspartyl-L-glutamate peptidase I, NAALADase I, prostate specific membrane antigen, EC and Attractin were proposed to belong to this group on the basis of the presumed DPP-IV-like enzymatic activity [24]. However, further research did not confirm the hydrolytic potential of these molecules [25, 26]. Since both of them also lack any significant structural homology with DPP-IV, they are no more included in the DASH group.

1.1.1. Dipeptidyl peptidase-IV

In humans, the canonical DPP-IV is almost ubiquitously expressed as a single-pass type II integral transmembrane glycoprotein in a variety of cell types, tissues and organs (reviewed in [11, 27]). Its soluble counterpart is detectable in body fluids, being either a product of proteolytic shedding from the cell surface or a putative specific secretory form [28]. Upregulation of the plasma membrane DPP-IV is associated with cell differentiation in e.g. T cells [29, 30], hepatocytes [31] and intestinal epithelium [32]. The expression and function of DPP-IV/CD26, a marker of a subset of activated T-cells, was intensively studied in the immune system [33]. Its crosslinking in T cells affects the synthesis and secretion of a number of cytokines and interleukins [34, 35]. DPP-IV is also identical with the adenosine daeminase binding protein and participates on the immunoregulations by influencing the pericellular concentration of free adenosine [36, 37]. The physiological relevance of the interaction of DPP-IV with plasminogen 2 [38] and several proteins of the ECM [39, 40] is still more speculated than proven.

1.1.2. Fibroblast activation protein

Possessing about 52% amino acid sequence identity with DPP-IV, FAP represents its closest homologue within the DASH group. Its gene is located on chromosome 2q23 and is believed to be a product of DPP-IV gene duplication (reviewed in [15]). FAP is typically expressed as a type II transmembrane protein and its soluble counterpart is present in blood plasma and is also known as α2-antiplasmin cleaving enzyme [41, 42]. In contrast to DPP-IV, FAP expression is substantially restricted and the majority of normal adult cells are FAP negative [27]. FAP expression is significantly induced in non-malignant states associated with tissue remodeling such as wound healing, embryogenesis, osteoarthritis as well as rheumatoid arthritis [43, 44], in liver cirhosis [45], and in cancer stroma [46]. In addition to the DPP-IV-like exopeptidase activity, FAP also possesses gelatinolytic endopeptidase activity [47, 48], and was thus suggested to participate in the degradation of structural proteins of the extracellular matrix during tissue remodeling and cancer cell invasion (reviewed in [15]). Matrix metalloproteinases (MMP), in particular MMP 2 [49], seem to be important functional partners of FAP in the modification of extracellular matrix [15]. Interestingly, heteromeric DPP-IV/ FAP complexes, possessing both the DPP-IV-like exopeptidase and proline-specific endopeptidase enzymatic activity, are suspected to influence the migratory and invasive potential of fibroblasts and endothelial cells [49, 50].

1.1.3. Dipeptidyl peptidase 8 and 9

DPP8 and 9 are cytosolic dimeric proteins that are expressed in the majority of tissues including the human brain [13, 14, 51, 52], for review see [53]. The enzymatic activity of DPP 9 is thought to be important for the degradation of intracellular proline containing proteins with presentation of the peptide fragments on MHC-I molecules [54]. Some reports also suggest the involvement of both DPP8 and 9 in the processes of cell growth, migration and adhesion, probably via an indirect, enzymatic activity independent effect on the cell-extracellular matrix interactions [55]. DPP 9 may also influence the intracellular signaling cascades: DPP9 overexpression reduces the EGF mediated Akt activation by an enzyme activity dependent mechanism, and in addition DPP9 interacts with Ras [56]. Both proteases are expressed in the immune system [52, 57] and some of the effects of non-selective DPP inhibitors on immune cells may be in fact caused by the inhibition of DPP8 and 9 [53].

1.1.4. Dipeptidyl peptidase-II

DPP-II (DPP7, QPP, EC possesses the unique DPP-IV-like enzymatic activity, but is structurally different from the canonical DPP-IV. It is a widely expressed intracellular enzyme that is typically localized in lysosomes and extralysosomal vesicles [16]. It is the only enzyme from the DASH group that has an acidic pH optimum [16]. Although the physiological function of DPP-II remains largely unknown, it is speculated to participate on the intralysosomal turnover of short peptides [58, 59]. In addition, several reports from the Huber lab argue for its role in the maintenance of quiescence in lymphocytes and fibroblasts [60, 61] and possibly also in glucose homeostasis [62]. DPP-II knockout is embryonic lethal in mice [62, 63], inhibition of DPP-II triggers apoptosis in noncycling G0 lymphocytes [64, 65] probably through deregulation of the cell cycle entry, and its absence in T cells leads to faster proliferation and differentiation into Th17 cells [63].

1.1.5. Dipeptidyl peptidase 6 and 10

DPP6 (dipeptidyl peptidase-IV like protein 1, DPPX) [66] and DPP10 (dipeptidyl peptidase-IV like protein 2)[67] are the enzymatically inactive, DPP-IV structurally related members of the DASH group [17]. Both proteins participate on the regulation of the voltage gated potassium channels [68] and may play a role in the development of the central nervous system and neurodegenerative diseases [69, 70]. There are currently no data on their role in gliomagenesis and only two studies suggested an association of mutations in DPP6 with pancreatic cancer [71, 72].

A substantial leap of interest in the DASH molecules was induced i) by the introduction of DPP-IV inhibitors in the treatment of type II diabetes [19, 244] and ii) observations of marked alterations of their expression and activity in the course of several diseases especially involving the immune system, and in cancer, where a direct pathogenetic role for DPP-IV and FAP seems to be highly probable. A significant proportion of the biologically active, mostly pro-proliferative peptides, systemic as well as local hormones, chemokines, neuropeptides, incretins and growth factors (Figure 1) contains a penultimate N-terminal proline residue as an evolutionary conserved proteolytic regulatory “check-point” [245]. Thus, the DPP-IV enzymatic activity is believed to be a functional regulator of their biological action. Limited proteolysis of these peptides by DPP-IV may lead both to quantitative and, due to the diversification of receptor subset preference, also to qualitative changes of their signaling potential [73-75].

While the systematic description of individual DASH molecules is available, including the cloning and structure resolution, the interpretations of biological studies are often equivocal because of their “moonlighting” character [76]. First, the overlap of enzymatic activities among the DASH molecules implies their sharing of similar sets of substrates (Figure 1) and thus, to some extent, DASH molecules may substitute each other. Second, DASH molecules execute more biological functions, depending on the given cell population and actual context of the biologically active substrates and the relevant receptors within the immediate environment. Third, the functional potential of DASH molecules is broadened by interactions with non-hydrolytic molecular partners (Ramirez-Montagut et al. 2004; Wang et al. 2005).


2. Expression and function of dipeptidyl peptidase-IV and related proteases in the microenvironment of human malignancies

2.1. Expression in transformed cells- tumor type specific and context dependent functions

Altered expression of DPP-IV and FAP is associated with several malignancies including brain tumors [87]. Both molecules may be expressed by the transformed as well as stromal cells and are associated with tumor promotion or suppression depending on the cancer type (for review see [88, 89, 27]). The mechanisms by which these molecules contribute to cancer pathogenesis and progression remain largely unknown, but several reports indicate that DASH molecules may serve as diagnostic and prognostic markers as well as therapeutic targets.

Figure 1.

Potential overlaps of DPP-IV and related proteases in the processing of biologically active peptides. The pathophysiological importance of the cleavage is established e.g. for GLP-1, GIP, CXCL12 and NP Y, some of the in vitro cleaved substrates are unlikely to be of significance in vivo (e.g. Heat shock protein 1 for DPP-IV, SPRY2 for FAP). Not all identified DPP-IV substrates were tested with DPP8, 9 and FAP, the cleavage by these proteases is usually slower compared to DPP-IV. * cleavage has only been established for DPP-IV and DPP8; ** substrates of the endopeptidase activity of FAP; *** only tested for DPP8 and DPP9; VIP= Vasoactive intestinal peptide, PACAP= Pituitary adenylate cyclase-activating peptide, GRP= Gastrin-releasing peptide, GIP= Gastric inhibitory polypeptide/ glucose-dependent insulinotropic peptide, PHM= Peptide Histidine-Methionine, GHRH= Growth hormone releasing hormone, BNP= Brain natriuretic peptide, SP= Substance P, GLP-1, 2= Glucagon-like peptide-1, 2, PYY= Peptide YY, NP Y= Neuropeptide Y, SPRY2= sprouty (Drosophila) homolog 2, RU1(34-42)= antigenic peptide VPYGSFKHV. Compiled based on [15, 54, 73, 77-86].

DPP-IV expression is typical for a subset of aggressive T cell malignancies, which may be related to its function in T cell activation [90, 91]. The presence of DPP-IV is also associated with a more malignant behavior in B-cell chronic lymphocytic leukaemia [92], thyroid cancer [93], gastrointestinal stromal tumors [94], and was recently linked to a subpopulation of cancer stem cells responsible for the metastatic spread of colorectal cancer [95].

Recent studies aimed at examining the functional role of DPP-IV in malignant cells. In mesothelioma, DPP-IV is expressed in tumors in situ and in mesothelioma cell lines [96]. By binding fibronectin and collagen I, DPP-IV likely contributes to the interaction of these cells with the ECM [97]. A different mechanism may operate in Ewing sarcoma: DPP-IV (and likely also the intracellular proteases DPP8 and 9) proteolytically cleaves NP Y1-36 to NP Y3-36 and thus abolishes its cell death inducing activity in the cancer cells and switches it to an angiogenesis promoting mediator [98].

Contrary to the above cited reports, some malignancies exhibit decreased DPP-IV expression. This is typical for melanoma and melanoma derived cell lines [99-102], cancer cell lines derived from neuroblastoma [103] and prostate [104] as well as non-small-cell lung cancer [105]. It should be however noted that on the tissue level, the data on DPP-IV expression are equivocal at least for prostate and lung cancer [106-109]. DPP-IV was shown to act as a tumor suppressor in melanoma [99, 102], neuroblastoma [103], prostate [104] and non-small-lung cancer [105] cells: its reexpression in the transformed cells led do decreased growth, increased apoptosis and sensitivity to growth factor withdrawal, decreased invasiveness and slower xenotransplant growth in immunodeficient animals.

The mechanisms that account for these diverse effects of DPP-IV on tumor cells are rather poorly understood. The currently best characterized physiological function of DPP-IV is proteolytic inactivation of incretins and possibly other biologically active peptides [73, 110]. The biological relevance of this phenomenon is confirmed by the clinically exploited DPP-IV inhibitors resulting in systemic elevation of DPP-IV substrates such as GLP-1 [111]. In addition, a variety of growth factors, chemokines and neuropeptides implicated in the progression of human tumors are potential DPP-IV substrates (reviewed in [74]) and DPP-IV may therefore act as a “gate-keeper” regulating their biological function on the systemic and/or local level. The decreased clearance of biologically active substrates due to the absence of DPP-IV may lead to sustained pro-proliferative signaling and promote tumor growth and metastasis. Masur et al. [112] showed that the growth promoting and promigratory activity of GLP-2 in colon cancer cells in vitro is increased in the presence of a DPP-IV inhibitor. Similarly, the inhibition of the DPP-IV enzymatic activity facilitated metastatic spread of prostate cancer cells by preventing the cleavage of the chemokine CXCL12 (SDF-1, stromal cell derived factor -1) [113].

On the other hand, DPP-IV also triggers changes in signaling cascades and expression of molecules mediating interaction with the ECM that are harder to reconcile with the cleavage of biologically active substrates in the pericellular space. In ovarian carcinoma, DPP-IV expression led to suppression of MAPK signaling, enhanced E-cadherin expression and the downregulation of MMP-2 and MT-MMP-1, which was associated with decreased invasiveness, tumor progression and enhanced chemosensitivity [114-116]. In prostate cancer cells, re-expression of DPP-IV interfered with the signaling of a non-DPP-IV substrate bFGF and inhibited their malignant phenotype in the study by Wesley et al. [104]. Yet, Goznalez-Gronow et al. [117] identified DPP-IV as a receptor for plasminogen 2 epsilon that promoted the invasiveness of the prostate cancer cell line 1-LN.

To test the relevance of the hypothesized non-proteolytic functions of DPP-IV, several groups including ours engineered an enzymatically inactive form of DPP-IV with a single amino acid substitution in the active site (Ser630→Ala630). Reintroduction of this mutant form of DPP-IV frequently results in similar tumor suppressing effects as observed with the enzymatically active DPP-IV [99, 102, 105, 118].

The proteolytic and non-proteolytic mechanisms may also combine and thus extend the portfolio of the biological functions of DPP-IV. Arscott et al. [103] showed that DPP-IV reexpression in neuroblastoma cells induced differentiation, increased their sensitivity to serum withdrawal and reduced their migration, invasion and pro-angiogenic capacity in vitro as well as in vivo. This was most likely caused by the downmodulation of the CXCL12-CXCR4 axis and possibly also other chemokine systems. Although not specifically demonstrated by the authors, DPP-IV most likely inactivated CXCL12 proteolytically, resulting in the downregulation of its downstream effectors, but in addition it downregulated the mRNAs of CXCL12 and CXCR4 and several other chemokines including non-DPP-IV substrates [103].

FAP was originally described to be typically expressed in the stromal compartment of tumors (see section 2.2), but several reports, including ours, also show its expression in the transformed elements. A prototypical example is the LOX melanoma cell line, where FAP co-localizes with the urokinase plasminogen activator receptor (uPAR) on the invadopodia and likely contributes to the pericellular proteolysis and invasiveness of these cells [119, 120, 47, 121, 122]. Somewhat surprisingly, Ramirez-Montagut et al. [123] were able to show that in mouse melanoma cells FAP may actually act as a tumor suppressor with the main effects on cell growth and survival independently of its enzymatic activity. These results are in agreement with Rettig et al., who observed loss of FAP during Ras mediated transformation of melanocytes [124] and with the fact that FAP is upregulated upon reintroduction of DPP-IV into melanoma cells with the resulting tumor suppressing effects [99]. Similarly, FAP negative subclones in osteosarcoma were tumorigenic and grew to high densities in contrast to non-tumorigenic FAP positive subclones [124].

Breast cancer cells also express FAP in vivo [15, 125]. FAP is associated with their decreased dependence on growth factors in vitro and formation of more rapidly growing and more vascularized tumors in a xenotransplantation model [125-127]. Interestingly and somewhat in contrast to the previously published data in other cancer types, the tumor promoting activities in breast cancer cells may be independent of the intrinsic enzymatic activity of FAP [128]. FAP is also expressed in the tumor cells of mesenchymal origin in malignant and benign tumors, but is probably rather linked to their myofibroblastic differentiation than to their malignant potential [129]. Epithelial cancer cells e.g. in gastric [130], esophageal [131], colorectal [132] and cervical cancer [133] were also demonstrated to be FAP positive. The function of FAP in these cells is unclear but in analogy to other cancers it is presumed to be linked to their invasiveness.

There is limited data on the expression and in particular the function of DPP8, DPP9 and DPP-II in cancer cells. Yu et al. described increased DPP9 mRNA in testicular cancers on a small patient sample [52], both DPP8 and DPP9 are expressed in human breast, ovarian and hepatic cancer cells as well as in lymphoma cells lines [52, 134] and chronic B cell leukemia cells [135]. Interestingly, transgenic DPP9 was shown to induce apoptosis in hepatoma cells and decrease the EGF mediated activation of Akt [56]. These effects were dependent on the enzymatic activity of DPP9, but in addition to that, both DPP9 and DPP8 were demonstrated to interact with Ras [56]. In Ewing sarcoma cells, DPP8 and DPP9 seem to exert similar effects as DPP-IV (see above) due to their similar enzymatic activity [98] and efficient cleavage of NP Y [77](Figure 1.). Whether DPP8 and DPP9 regulate the adhesion and migration [55] of malignant cells remains to be established. Lower DPP-II catalytic histochemistry staining was suggested as a favorable prognostic marker in chronic lymphocytic leukemia (CLL) [136]. In addition, DPP-II inhibition leads to induction of apoptosis in CLL cells in approximately 60% of patients, which is associated with the presence of other established positive prognostic markers and a clinically more benign disease course [137]. Whether DPP-II is functionally involved in the pathogenesis in CLL and/or other cancers is currently not known.

2.2. Expression and role of dipeptidyl peptidase-IV and related proteases in the stromal compartment of tumors

Tumor stroma is composed of an extracellular matrix and a diverse set of cell types that significantly contribute to tumor progression [138]. Among others, the stroma is an important source of tumor associated proteases including the DASH molecules.

Vascular and lymphatic endothelial cells express DPP-IV in cell culture as well as in situ [139, 140], but the expression is variable and several reports show no DPP-IV staining of cell vessels [141]. Similarly ambiguous are the data regarding the function of DPP-IV in endothelial cells: it is speculated to contribute to their interaction with the extracellular matrix proteins, convert NP Y to its pro-angiogenic form and promote their migration and invasion [50, 142-144]. Contrarily, a recent report showed that DPP-IV ablation using either genetic or pharmacologic approaches may increase endothelial cell proliferation and migration induced by the inflammatory cytokines TNF-α or IL-1β [139]. These somewhat conflicting results may be due to regional differences in the proteolytic makeup of endothelial cells as well as differing functions of DPP-IV depending on the presence of its “molecular partners” and microenvironmental stimuli. FAP mRNA was also detected in endothelial cells cultured in vitro [145]. Interestingly, Ghilardi et al. [146] observed higher FAP expression in endothelial cells derived from ovarian and renal carcinoma compared to cells derived from normal tissues. The functions of FAP in endothelial cells are mostly speculative but it may (probably together with DPP-IV) contribute to the degradation of extracellular matrix [50]. FAP may be also expressed by pericytes [138], although in some cancer models its expression was restricted to isolated infiltrating stromal cells rather than pericytes [147].

Expression of DPP-IV in the normal and cancer associated fibroblasts is rather variable [148-151], but cultured fibroblasts and myofibroblasts in the majority of epithelial cancers strongly express FAP [15, 152, 153]. Stimuli leading to the upregulation of FAP may involve inflammatory mediators such as TGF beta, Il1 and oncostatin M [43, 154], factors secreted by tumor cells (i.e. PDGF-BB, TGF-beta1 and Wnt5a in melanoma cells [155]) and the transcription factor EGR1 [156]. Pathophysiologically, FAP likely participates in the turnover and modification of the extracellular matrix [157]. Lee et al. [158] found that fibroblasts engineered to express FAP seeded on gelatin produced matrices with changed composition and structure, which promoted the migratory behavior of pancreatic carcinoma cells. These changes were mediated by the enzymatic activity of FAP as demonstrated by using a FAP inhibitor naphthalenecarboxy-Gly-boroPro [158]. FAP inhibition was also shown to block the growth of lung and colon cancer in a mouse model by increased accumulation of collagen, decreased myofibroblast content and vessel density [159] suggesting its crucial role for the effective establishment of tumor stroma. Other mechanisms may also contribute to the important role of FAP in tumor microenvironment. By selectively depleting the FAP positive stromal cells, Kraman et al. demonstrated that they are crucial for the suppression of antitumor immune response [160]. Whether FAP is just an “innocent by-stander” marker of these cells, or plays a direct role in this process remains to be established. In multiple myeloma, the stromal FAP expression is important in promoting the survival of myeloma cells [18, 161], but the mechanisms are unknown. The expression of FAP in tumors is in general associated with a more aggressive disease course and shorter patient survival [153, 162, 163]. Surprisingly, one study in breast cancer [164] described longer overall survival and the disease free interval in patients with higher stromal FAP expression.

Immune cells are another important constituent of the tumor microenvironment that may express DPP-IV, DPP8 and DPP9, but do not express FAP [135, 165, 166]. In cancer patients, changes in the DPP-IV levels are frequently seen in serum and in lymphocytes [80] and cytokines such as TGF-β may contribute to these changes in peripheral blood lymphocytes as documented in patients with oral cancer [167]. Despite the well established role of DPP-IV in human lymphocyte proliferation and activation [33], its function, as well as the possible significance of DPP8 and DPP9 in mediating or suppressing effective antitumor responses is unknown. Talabostat (PT-100), an inhibitor of DPP-IV and FAP, was demonstrated to stimulate the immune response to several experimental tumors, but the mechanisms were not dependent on the inhibition of DPP-IV [168].

In conclusion, the expression of DPP-IV and related proteases is frequently deregulated in the parenchymal and/or stromal compartment in human malignancies. The molecules may promote or suppress tumor progression depending on the tumor type and the presence of their substrates and/or interactors in the microenvironment, which are characteristic for individual tumors. This highly context dependent role is the likely explanation for the conflicting data reported on their role in cancer [27, 74, 169]. The mechanisms seem to involve proteolytic processing as well as non-proteolytic protein-protein interactions and modification of intracellular signaling pathways. Similar mechanisms likely operate for the intracellular proteases DPP8 and DPP9, but the evidence for their role in human cancers is currently limited.


3. Dipeptidyl peptidase-IV and related proteases in the pathogenesis of brain tumors

3.1. Expression of DPP-IV and related proteases in glioma cell lines

In astrocytoma cells, DPP-IV was first detected using immunohistochemistry by Medeiros [170]. Subsequent work in our laboratory revealed the presence of DPP-IV-like enzymatic activity together with the expression of mRNA for DPP-IV, FAP and DPP-8 and 9 in permanent glioma cell lines C6, U373, T98G, U251, U87, U138, U118 and in human glioma primary cell cultures as well as in glioma stem-like cells ([118, 171-175] and unpublished data). The DPP-IV-like enzymatic activity in the permanent glioma cell lines is only partially inhibited by a highly specific DPP-IV inhibitor sitagliptin. In U87, U138 and U118 lines 30, 60 and 85% respectively of the total enzymatic activity is inhibited and can therefore be attributed to the canonical DPP-IV. In contrast, only 12-15% of the DPP-IV-like enzymatic activity in U373, T98G, U251 cells is inhibited by sitagliptin (Busek et al. unpublished data). These results correspond well with the relatively high DPP-IV mRNA expression in the U87, U138 and U118 cell lines [175, 176].

FAP is also expressed in glioma cells. The early work by Rettig et al. [177] detected FAP in 19 out of 22 of astrocytoma cell lines by immunohistochemistry using the F19 monoclonal antibody. Similarly Mentlein et al. [176] showed high FAP mRNA expression in 6 out of 7 glioma cell lines. According to our data, the expression of FAP may be more variable [118] with substantial variation in individual primary cell cultures as well as permanent cell lines. In the panel of glioma cell lines examined in our studies, FAP expression mirrored the expression of DPP-IV and was substantially higher in U87, U138 and U118 cell lines than in U373, T98G, U251 lines [175]. Therefore, although FAP is significantly less efficient in cleaving the H-Gly-Pro-AMC substrate compared to DPP-IV [48], it may partly contribute to the sitagliptin resistant DPP-IV-like enzymatic activity in some of the glioma cells lines. Interestingly, we have consistently observed a positive correlation between the mRNA expression of the two transmembrane proteases DPP-IV and FAP in glioma cell lines as well as in glioma primary cell cultures [178]. Moreover, the expression of both DPP-IV and FAP increased concomitantly in glioma cells cultured in serum free media and decreased after the addition of serum to the starved cells [178] suggesting that similar pathways regulate their expression in this model, most likely on the transcription and/or mRNA stability levels [178]. The mRNAs for the ubiquitous intracellular enzymes DPP8 and DPP9 are expressed in similar quantities in the glioma cell lines tested in our laboratory and probably make the largest contribution to the residual DPP-IV-like enzymatic activity after inhibition with sitagliptin (Busek et al. unpublished data).

It is currently unclear to what extent the in vitro cell culture conditions and the standard process of glioma cell line establishment may influence the observed expression of DPP-IV and especially FAP, a known phenotypic marker of mesenchymal cells such as activated fibroblasts [15]. The typical media supplemented with 10% fetal calf serum are known to promote the mesenchymal phenotype in cultured cells (“mesenchymal drift”; [179]) which could lead to the upregulation of FAP. Xenotransplants generated by orthotopic implantation of the glioma cells into immunodeficient mice exhibited higher DPP-IV-like enzymatic activity compared to the contralateral hemisphere (Figure 2) and the enzymatic activity was in part sensitive to a specific DPP-IV inhibitor. DPP-IV as well as FAP could be detected on the mRNA level as well as by immunohistochemistry in the xenotransplants from the U87 and U138 cells (data not shown), which suggests that their expression in glioma cells is retained under the conditions closely mimicking the microenvironment of human gliomas. Similarly, Li et al. [180] were able to demonstrate the enzymatic activity of FAP in a U87 tumor model, although the subcutaneous implantation used in their study exposed the glioma cells to somewhat unnatural microenvironment. Orthotopic xenotransplantation of freshly isolated glioma cells or expanded glioma stem-like cells are necessary to determine whether the expression of FAP in particular is maintained in glioma cells in situ. Such experimental approach would be suitable for the preclinical tests of therapies targeting this protease.

Figure 2.

DPP-IV-like enzymatic activity detected by catalytic histochemistry in orthotopic glioma xenotransplants (A-C). 106 cells of the indicated cell lines were used for intracerebral implantation into immunodeficient mice [118]. DPP-IV-like enzymatic activity (red precipitate) was detected by incubating 10μm frozen sections with 7-(glycyl-l-prolylamido)-4-methoxy-β-naphthylamide hydrochloride as a substrate and Fast Blue B in PBS (pH 7.4) at 4°C overnight [181]. 1μM sitagliptin was used to inhibit the enzymatic activity of canonical DPP-IV (CD26), nuclei were counterstained with haematoxylin. Only small areas of DPP-IV-like enzymatic activity (arrows) can be detected in U373 tumors (A). In (B), the dashed line marks the interface between the diffusely stained tumor tissue and surrounding normal brain (asterisk). (D) DPP-IV-like enzymatic activity in homogenates from the xenotransplants compared to the contralateral hemisphere. H-Gly-Pro-7-amino-4-methylcoumarin was used as a substrate at pH 7.5 and 37°C [118].

3.2. Expression of DPP-IV and related proteases in normal brain and human astrocytic tumors

The data on the expression of DPP-IV, DPP-II, FAP and DPP8 and 9 in the human brain is limited. Using immunohistochemistry, Bernstein et al. detected abundant expression of DPP-IV in the immature central nervous system with much lower expression in adults [246]. In rats, mice and ginea-pigs, the expression of DPP-IV was studied in more detail and DPP-IV was detected in the capillaries, meninges as well as certain neuronal structures (see [175] and references therein). By means of its enzymatic activity, DPP-IV is speculated to participate on nociception and behavior regulation most likely by inactivating biologically active peptides such as SP, endomorphin-2 and NP Y [182-184]. DPP-IV may also be involved in the pathogenesis of ischemia-reperfusion injury. Roehnert et al. [185] described the appearance of DPP-IV immunoreactivity in rat microglia, astrocytes and neurons following unilateral transient occlusion of the medial carotid artery. Interestingly, intracranial administration of a specific DPP-IV inhibitor sitagliptin led to a 21.1±5.8% decrease in infarct size suggesting neuroprotection in this model [185].

Enzymatic activity attributed to DP-II was detected in brain homogenates [186, 187] and histochemically in specific neuronal populations in rat brain by Gorenstein et al. [188]. Later studies demonstrated its presence in glial cells [189] and speculated its association with astrocyte differentiation [190].

DPP8 and 9 are also expressed in the brain tissue [13, 52] and are probably responsible for a significant part of the DPP-IV-like enzymatic activity detected in human brain tissue homogenates [87]. In rats, DPP8 was detected in neurons, but not astroglial cells and microglia by immunohistochemistry [185].

On the contrary, FAP protein is most likely absent in non-tumorous human brain: Rettig et al. [177] failed to detect its expression in human autopsy material using the F19 antibody; similarly, samples obtained from patients with pharmacoresistant epilepsy show no staining using several anti FAP antibodies ([87] and unpublished data). Although FAP mRNA can be detected by sensitive RT-qPCR assays [87, 176], it is probably not being translated or the protein levels are bellow the detection limit of the methods used.

In gliomas the DPP-IV-like enzymatic activity is substantially higher compared to the non-tumorous brain [87, 191] and DPP8 and 9 represent the major part in both cases [87]. In contrast to DPP8 and 9, the expression of DPP-IV and FAP is significantly increased in gliomas compared to the non-tumorous brain. According to The Cancer Genome Atlas ([192], DPP-IV and FAP mRNA are upregulated more than two times compared to controls in 200 of 424 (47%) and in 162 of 424 (38%) glioblastoma patients respectively. In our patient cohort ([87] and unpublished data) DPP-IV and FAP mRNA were upregulated 9.9 and 4.6 fold respectively in newly diagnosed glioblastoma (N=28) compared to controls (pharmacoresistant epilepsy, N=15). Using RT-qPCR, Mentlein et al. also observed upregulation of DPP-IV and FAP in a small cohort of glioblastoma patients compared to the autopsy material [176]. Similarly, increased FAP expression in grade IV tumors and especially in gliosarcomas was observed by Mikheeva et al. [193].

Using catalytic histochemistry, Mares et al. could show that the DPP-IV-like enzymatic activity in grade II astrocytomas was mainly localized perivascularly and in mononuclear-like cells in the parenchyma [191]. In grade IV tumors (glioblastomas), the proportion of these stained cells was markedly increased and in addition, the DPP-IV-like enzymatic activity was present in spindle shaped, smooth muscle- or pericyte-like cells around hyperplastic vessels, and in tumor parenchyma [191]. Interestingly, the overall DPP-IV-like enzymatic activity determined by catalytic histochemistry correlated negatively (r= -0.30, p= 0.04) with the proliferation marker Ki67 [191]. Immunohistochemistry staining with DPP-IV and FAP specific antibodies revealed minimal positivity in non-tumorous brain with frequent fiber-like positivity in glioblastomas, occasionally close to the capillaries [191]. Mentlein et al. showed that at least part of the FAP expressing cells also coexpressed GFAP and Ki67 [176]. Collectively, these data demonstrate that the expression of DPP-IV and FAP as well as the DPP-IV-like enzymatic activity is increased in a substantial part of glioblastomas. Both the transformed as well as stromal cells such as reactive astrocytes, cells in the vessel wall and infiltrating immune cells may contribute to this increased expression.

3.3. Possible functions of DPP-IV and FAP in the glioma microenvironment

Glioblastomas are highly heterogenous both histologically and on the molecular level [194, 195]. The transformed cells themselves represent a mixture of cell types that may originate from the stochastic clonal expansion or from a more hierarchical organization of gliomas as postulated by the cancer stem cell hypothesis [196, 197]. In addition to the transformed cells, a variety of host cells contributes to the glioma microenvironment. This stromal compartment is an important contributor to the malignant phenotype of glioma cells and comprises of microglia/macrophages, lymphocytes, neural precursor cells, neurons, pericytes/vascular smooth muscle cells, reactive astrocytes and endothelial cells [198].

Given the marked increase of the expression of DPP-IV and FAP mRNA in glioblastoma tissue homogenates and the increase of the DPP-IV-like enzymatic activity in the microvasculature and parenchyma, the proteases seem to be functionally important for the transformed as well as nontransformed cells.

3.3.1. DPP-IV as a possible regulator of glioma cell growth

The DPP-IV-like enzymatic activity may influence signaling of various soluble mediators involved in the pathogenesis of gliomas (Table 1).

DPP-IV substrate Role in gliomagenesis
CCL3L1 (LD78beta) Enhances glioma cell proliferation[199].
CCL5 Possible role in the recruitment of microglia/macrophages [200], promotion of glioma invasion and angiogenesis [201].
CCL22 Recruitment of immunosuppressive Treg cells [202, 203].
CXCL9 Increased expression in glioblastoma [204], promotes glioma cell growth [205].
CXCL10 Pro-proliferative signaling through ERK1/2 in glioma cells [205, 206].
CXCL11 A ligand for CXCR7, which mediates prosurvival signaling in glioma cells [207, 208].
CXCL12 Promotion of glioma invasion, growth and angiogenesis (for review see [209])
SP Promotion of glioma growth and secretion of cytokines (reviewed in [210, 211]).
PACAP, VIP Stimulation of glioma cell growth [212, 213].

Table 1.

DPP-IV substrates implicated in the pathogenesis of gliomas

Although DPP-IV and FAP exhibit similar dipeptidyl peptidase activity on small fluorogenic substrates, a recent study found substantial differences in their ability to cleave peptide substrates [79]. All peptides (with the exception of VIP) listed in Table 1 are cleaved rapidly by recombinant DPP-IV; in contrast FAP can only cleave SP effectively and does not cleave chemokines, PACAP or VIP [79](Figure 1). Given that, DPP-IV is the main candidate for influencing the functions of these mediators in gliomas.

By removing the N-terminal dipeptide from the biologically active peptides, DPP-IV in general diminishes their activity and/or increases their susceptibility to cleavage by other proteases [73]. Given that the majority of the substrates listed in Table 1 are thought to promote the malignant phenotype of glioma cells, DPP-IV would be somewhat paradoxically expected to suppress it. Indeed, we have previously shown the ability of DPP-IV to abrogate the calcium mediated signaling of SP in glioma cells [214]. We also observed that higher DPP-IV-like enzymatic activity in primary glioma cell cultures correlated with their slower growth [118]. In addition, overexpression of the transgenic DPP-IV in several glioma cell lines decreased their proliferation, led to a cell cycle block and a 50% decrease of the size of xenotransplanted tumors in immunodeficient mice [118]. Interestingly, our microarray data suggested that expression of several molecules linked to glioma pathogenesis was perturbed in glioma cells with forced expression of DPP-IV [118]. This included e.g. downregulated expression of transcripts encoding membrane growth factor receptors (PDGFRA, CALCRL, GRPR) and adhesion molecules (CD97, COL8A1, COL13A1, NLGN1, NLGN4X, PCDH20, SCARF2, NrCAM) as well as molecules typically overexpressed in gliomas (e.g. CALCRL, COL8A1, HAS2, NES, RRM2 [192], On the contrary, several tumor suppressors e.g. BEX2, RAP1GAP, DUSP26, SYT13, TSPYL2 were upregulated ([118] and references therein). In order to determine whether the observed in vitro and in vivo growth inhibitory effects were mediated by the enzymatic activity, the experiments were done in parallel with cells transfected with an enzymatically inactive mutant DPP-IV due to a single amino acid (Ser630→Ala630) substitution in the active site [118]. These studies revealed similarly decreased growth of glioma cells overexpressing the enzymatically inactive DPP-IV providing evidence that these effects were independent of the enzymatic activity [118]. In summary, our studies demonstrate that DPP-IV may modify the function of its substrates through proteolysis, but likely has also an enzymatic activity independent growth inhibitory effect in glioma cells. The detailed molecular mechanism(s) for these effects however remain to be identified.

These data strongly argue that DPP-IV in glioma cells in vivo is unlikely to directly promote the malignant potential of the expressing cells. However, DPP-IV did not suppress the malignant phenotype of glioma cells completely in our studies – albeit the tumors were smaller with lower percentage of Ki67 positive nuclei, they exhibited an infiltrative growth pattern similar to controls [118]. We also observed a highly infiltrative growth of the xenotransplanted glioma stem-like cells expressing DPP-IV (Busek et al. unpublished). Several possibilities exist to explain these seeming contradictions: i) DPP-IV expression / enzymatic activity may reflect a mechanism striving to prevent the inappropriate proliferation of malignant cells. In support of this possibility, Mares et al. [191] observed an inverse correlation between the DPP-IV-like enzymatic activity and Ki67 in glioblastoma tissues. On the other hand, these less proliferative cells may be more resistant to conventional adjuvant therapies and therefore contribute to tumor recurrence. ii) Glioblastomas are highly heterogeneous and likely composed of several interacting subpopulations establishing a complex “ecosystem” [197]. DPP-IV may contribute to the interaction with other tumor clones and/or stromal compartment by local proteolytic processing of biologically active peptides with an overall increased tumor growth despite its growth inhibitory effects in the expressing subpopulation. Such a role of DPP-IV could not have been identified using conventional cell-line based xenotransplantation models in immunodeficient animals utilized in our studies. iii) DPP-IV expression may also be linked to the microenvironment typical of glioblastomas. The grade IV tumors characteristically contain necrotic areas and exhibit enormous stimulation of angiogenesis caused by hypoxia. Hypoxia also promotes the aggressiveness of glioma cells through the transcription factor HIF-1α (hypoxia inducible factor-1α) [215]. DPP-IV was demonstrated to be regulated by hypoxia in several systems although with variable outcomes. In extravillous trophoblast cells, the hypoxia induced increase of DPP-IV was associated with their decreased invasiveness [216]. In colon and gastric cancer cell lines, DPP-IV was increased in a HIF-1α dependent manner in response to hypoxia in vitro and in xenotransplants depleted of VEGF [217]. The purpose of this induction of DPP-IV in the response to hypoxia is not clear. The data from other experimental systems nevertheless suggest that by promoting the expression of DPP-IV together with the angiogenic receptor Y2, ischemia may enhance the angiogenic response to NPY [218, 219].

In addition to the transformed glioma cells, DPP-IV is also increased in the microvasculature [191]. Here, DPP-IV may contribute to neoangiogenesis by promoting the proliferation and invasiveness of endothelial cells.

In summary, higher expression of DPP-IV is typical for glioblastomas. Although the function of the protease cannot be currently ascribed with certainty, it may negatively affect glioma cell proliferation even independent of its enzymatic activity [118] and participate on the pericellular proteolysis with possible paracrine effects on other tumor subpopulations including stromal cells. The functional significance of DPP-IV upregulation in the glioma stromal compartment remains to be established.

3.3.2. Implications of FAP for glioma migration, ECM remodeling and angiogenesis

Several reports suggest a possible role of FAP in glioma cell migration not only because of its role in the extracranial malignancies (section 2.1). Lal et al. [220] studied the phenotypic and molecular changes caused by the introduction of the activating mutant form of EGFR (EGFRvIII) into glioma cells with low EGFR expression. They observed increased invasiveness of the EGFRvIII transduced cells, which was accompanied by upregulation of several transcripts encoding proteins of the extracellular matrix and proteases, including FAP [220]. A similarly designed study tested the effects of the introduction of IGFBP2, a molecule with pleiotrophic roles in glioblastoma [221], into the SNB19 glioma cell line. Here, increased invasion was also observed and FAP was among the 28 significantly induced genes with a 4.5 to 16 fold increase in different clones according to the microarray data [222]. Likewise, introduction of TWIST1, a basic helix-loop-helix domain-containing transcription factor implicated in EMT (epithelial mesenchymal transition) and cancer metastasis [223], into glioma cells promoted their invasion and among other genes activated the expression of FAP [193]. Tatenhorst et al. [247] took a different approach and compared the expression profile in two subpopulations isolated from the U373 glioma cell line based on their differing migratory rates on Matrigel. FAP was the top upregulated gene (11.7 fold) in the clone with high migration in vitro. Although these studies do not provide direct evidence that FAP contributes to the high migration and invasiveness characteristic for glioma cells, they strongly suggest an association of FAP expression with the glioma migratory phenotype and its activation in response to molecular abnormalities frequently occurring in glioblastomas. Mentlein et al. [176] addressed the role of FAP in glioma migration directly by siRNA mediated downregulation in the A746 glioma cell line. No effect on cell migration was noted in the transwell assay when uncoated or Matrigel coated inserts were used [176]. However, the cells invaded slightly less efficiently through the gelatin coated inserts and their invasion through brevican, a chondroitin sulfate proteoglycan abundantly present in the adult human brain, was reduced by almost 50% [176]. The underlying mechanisms remain to be established. The extracellular matrix of gliomas is substantially different from the extracranial malignancies: the fibrillary proteins (e.g. collagens, fibronectin, laminin) are much less abundant and mostly present in the perivascular space. Instead, hyaluronic acid and associated proteins such as versican and brevican prevail [224, 225]. Although Mentlein et al. [176] demonstrated that FAP cleaved brevican, the cleavage by the recombinant protease was inefficient and required prolonged incubations. Thus, the siRNA mediated downregulation of FAP in glioma cells could instead have effects on other ECM degrading systems. FAP is known to be part of multiprotein complexes in invadopodia [153, 226] and it was demonstrated to physically interact with uPAR in a β1-integrin dependent manner [121]. Interestingly, simultaneous downregulation of uPAR and cathepsin B was shown to downregulate FAP in glioma cells [227]. FAP therefore seems to act in cooperation with other proteolytic systems and its presence may influence the remodeling of glioma ECM not only by its intrinsic gelatinolytic activity but also by its possible role in the formation and/or stabilization of invadopodia.

Another interesting but unexplored aspect is the possible role of FAP in the promotion of angiogenesis of glioblastomas. The expression of FAP in endothelial cells [145, 146], higher microvessel densities in breast cancer xenotransplants engineered to express FAP [127] and the decreased microvessel density in response to FAP ablation in a lung cancer model consistently imply its role in angiogenesis. This may be –similarly to DPP-IV– via the processing of NP Y 1-36 to an angiogenic NP Y 3-36 [228]. In addition, FAP expressing fibroblasts are able to modify collagen type I matrices in a way that promotes the invasion of tumor cells (see section 2.2, [158]). Possibly, FAP may participate on the transformation of the glioma extracellular matrix into an environment that would be more supportive for the migration of endothelial cells [15].

Glioblastomas typically contain necrotic areas surrounded by pseudopalisades. A model for the pathogenesis of this typical morphological feature of glioblastoma has been proposed [229, 230] and postulates that thrombotic occlusion of the central vessel results in hypoxia, which than drives the migration of the surrounding glioma cells and robustly stimulates angiogenesis. Several mechanisms likely contribute to the vaso-occlusive process including the leakage of plasma clotting factors through the damaged vessels and their contact with a procoagulant tumor environment (see [231] for review). FAP was previously demonstrated to be identical with α2-antiplasmin cleaving enzyme [42]. Upon conversion by FAP, α2-antiplasmin is more effectively incorporated into fibrin and protects the fibrin clot from plasmin degradation [232]. By this mechanism, FAP may contribute to the prothrombogenic state in glioblastoma with resulting development of necrosis and stimulation of angiogenesis. The speculated mechanisms listed above are mediated by the DPP-IV-like or prolyl- endopeptidase enzymatic activities of FAP. In addition, FAP has probably other, enzymatic activity independent pro-angiogenic effects as recently demonstrated in breast cancer using catalytically inactive mutant FAP [15, 128].


4. DPP-IV and FAP as possible markers and treatment targets in gliomas?

Glioblastomas have dismal prognosis and despite the multimodality treatment the majority of patients die within 10-14 months [248, 249]. Regardless of ongoing efforts, the pathogenesis of glioblastoma remains unknown and therefore specific targeted therapies are currently not available. Despite their rather peculiar role in cancer pathogenesis, both DPP-IV and FAP were suggested as diagnostic and prognostic markers and therapeutic targets for tumors outside of the central nervous system (reviewed in [15, 88]). DPP-IV staining was suggested as a useful adjunct marker for the differentiation of malignant melanomas from deep penetrating nevi [101] and benign and malignant diseases of the thyroid gland [93, 233]. To the best of our knowledge, there is only one study suggesting a possible prognostic relevance of DASH molecules in the brain tumors. Shaw et al. [234] studied the expression signature that was related to the chemosensitivity of oligodendroglial tumors and observed that FAP was downregulated several fold in tumors that were chemosensitive and/or exhibited the prognostically favorable 1p/19q loss [234].

Preclinical studies with DPP-IV targeting antibodies suggest that DPP-IV may be a new therapeutic target in malignant mesothelioma [96, 97], renal carcinoma [235] and some hematologic malignancies [236]. The highly selective expression of FAP in the tumor microenvironment and its expected direct pathogenetic participation on tumor progression has also raised interest in its possible therapeutic exploitation with a simultaneous impact not only on the transformed cells, but also on the stromal elements („stroma targeted therapies“)[138]. Experimentally, FAP specific antibodies were utilized for the targeting of TNF alpha carrying nanoparticles [237] or in the form of a chimeric protein with the extracellular domain of the ligand of the TNF receptor 4-1BB to enhance the local T cell-mediated antitumor responses [238]. Further, induction of immune response against FAP leads to a decreased tumor growth and an enhanced effect of cytostatic therapy in several experimental models [239-242]. FAP activated cytotoxic prodrugs have also been designed [243] and the inhibition of FAP enzymatic activity by specific low molecular weight inhibitors was tested in experimental myeloma treatment [18].

Several important issues arise when designing treatment modalities targeting the DASH molecules by enzyme inhibitors or antibodies. In the case of DPP-IV, its almost ubiquitous presence, combined with multiple tissue specific biological roles, increases the risk of on-target side effects. In this respect, the restricted expression of FAP seems to be a substantial advantage. Further, the similar enzymatic properties of DASH proteases represent a possible source of off-target side effects [19]. Such a problem may be avoided by using highly specific inhibitors as documented by the successful introduction of DPP-IV inhibitors into clinical practice for the treatment of diabetes mellitus [244]. On the other hand, the moonlighting nature of the DASH molecules (combination of enzymatic and non-enzymatic functions), might hypothetically represent an advantage for their targeting as the non-enzymatic functions would remain untouched when using low molecular weight inhibitors to block the enzymatic functions.

In conclusion, given the emerging role of DPP-IV and FAP in the processes of gliomagenesis and the precedent evidence for their possible therapeutic exploitation in extracranial malignancies, they seem to be promising candidates for the targeting of gliomas.



This work was supported by grants IGA 12237-5/2011, PRVOUK-P27/LF1/1 and UNCE 204013.


  1. 1. Albesiano, E., J.E. Han, and M. Lim, Mechanisms of local immunoresistance in glioma. Neurosurg Clin N Am, 2010. 21(1): 17-29.
  2. 2. Waziri, A., Glioblastoma-derived mechanisms of systemic immunosuppression. Neurosurg Clin N Am, 2010. 21(1): 31-42.
  3. 3. Mentlein, R., Cell-surface peptidases. Int Rev Cytol, 2004. 235: 165-213.
  4. 4. Rao, J.S., Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer, 2003. 3(7): 489-501.
  5. 5. Lakka, S.S., C.S. Gondi, and J.S. Rao, Proteases and glioma angiogenesis. Brain Pathol, 2005. 15(4): 327-41.
  6. 6. Fukuda, M.E., et al., Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res, 2005. 65(12): 5190-4.
  7. 7. Takano, S., et al., Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity. Brain Tumor Pathol, 2010. 27(2): 89-94.
  8. 8. Hsu, D.W., J.T. Efird, and E.T. Hedley-Whyte, Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol, 1995. 147(1): 114-23.
  9. 9. Hopsu-Havu, V.K. and G.G. Glenner, A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie, 1966. 7(3): 197-201.
  10. 10. Nagatsu, I., T. Nagatsu, and T. Yamamoto, Hydrolysis of amino acid beta-naphthylamides by aminopeptidases in human parotid salva and human serum. Experientia, 1968. 24(4): 347-8.
  11. 11. Lambeir, A.M., et al., Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Critical Reviews in Clinical Laboratory Sciences, 2003. 40(3): 209-94.
  12. 12. Sedo, A., et al., Dipeptidyl peptidase IV in the human lung and spinocellular lung cancer. Physiological Research, 1991. 40(3): 359-62.
  13. 13. Abbott, C.A., et al., Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem, 2000. 267(20): 6140-50.
  14. 14. Tang, H.K., et al., Biochemical properties and expression profile of human prolyl dipeptidase DPP9. Arch Biochem Biophys, 2009. 485(2): 120-7.
  15. 15. Kelly, T., et al., Fibroblast activation protein-alpha: a key modulator of the microenvironment in multiple pathologies. Int Rev Cell Mol Biol, 2012. 297: 83-116.
  16. 16. Maes, M.B., S. Scharpe, and I. De Meester, Dipeptidyl peptidase II (DPPII), a review. Clinica Chimica Acta, 2007. 380(1-2): 31-49.
  17. 17. McNicholas, K., T. Chen, and C.A. Abbott, Dipeptidyl peptidase (DP) 6 and DP10: novel brain proteins implicated in human health and disease. Clin Chem Lab Med, 2009. 47(3): 262-7.
  18. 18. Pennisi, A., et al., Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease. Br J Haematol, 2009. 145(6): 775-87.
  19. 19. Lankas, G.R., et al., Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes, 2005. 54(10): 2988-94.
  20. 20. Bezerra, G.A., et al., Structures of Human DPP7 Reveal the Molecular Basis of Specific Inhibition and the Architectural Diversity of Proline-Specific Peptidases. PLoS One, 2012. 7(8): e43019.
  21. 21. Dubois, V., et al., Dipeptidyl peptidase 9 (DPP9) from bovine testes: identification and characterization as the short form by mass spectrometry. Biochim Biophys Acta, 2010. 1804(4): 781-8.
  22. 22. Ansorge, S., et al., Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med, 2009. 47(3): 253-61.
  23. 23. Rummey, C. and G. Metz, Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site. Proteins, 2007. 66(1): 160-71.
  24. 24. Sedo, A. and R. Malik, Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochimica et Biophysica Acta, 2001. 1550(2): 107-16.
  25. 25. Barinka, C., et al., Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. Journal of Neurochemistry, 2002. 80(3): 477-87.
  26. 26. Friedrich, D., et al., Does human attractin have DP4 activity? Biological Chemistry, 2007. 388(2): 155-62.
  27. 27. Yu, D.M., et al., The dipeptidyl peptidase IV family in cancer and cell biology. FEBS Journal, 2010. 277(5): 1126-44.
  28. 28. Durinx, C., et al., Molecular characterization of dipeptidyl peptidase activity in serum - Soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. European Journal of Biochemistry, 2000. 267(17): 5608-5613.
  29. 29. Morimoto, C. and S.F. Schlossman, The structure and function of CD26 in the T-cell immune response. Immunological Reviews, 1998. 161: 55-70.
  30. 30. Sato, K. and N.H. Dang, CD26: A novel treatment target for T-cell lymphoid malignancies? International Journal of Oncology, 2003. 22(3): 481-497.
  31. 31. Agarwal, S., K.L. Holton, and R. Lanza, Efficient differentiation of functional hepatocytes from human embryonic stem cells. Stem Cells, 2008. 26(5): 1117-27.
  32. 32. Darmoul, D., et al., Dipeptidyl peptidase IV (CD 26) gene expression in enterocyte-like colon cancer cell lines HT-29 and Caco-2. Cloning of the complete human coding sequence and changes of dipeptidyl peptidase IV mRNA levels during cell differentiation. Journal of Biological Chemistry, 1992. 267(7): 4824-33.
  33. 33. Dang, N.H. and C. Morimoto, CD26: an expanding role in immune regulation and cancer. Histology & Histopathology, 2002. 17(4): 1213-26.
  34. 34. Fan, H., et al., Dipeptidyl peptidase IV/CD26 in T cell activation, cytokine secretion and immunoglobulin production. Advances in Experimental Medicine & Biology, 2003. 524: 165-74.
  35. 35. Fleischer, B., CD26: a surface protease involved in T-cell activation. Immunol Today, 1994. 15(4): 180-4.
  36. 36. Franco, R., et al., Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. Immunol Rev, 1998. 161: 27-42.
  37. 37. Gorrell, M.D., V. Gysbers, and G.W. McCaughan, CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scandinavian Journal of Immunology, 2001. 54(3): 249-64.
  38. 38. Gonzalez-Gronow, M., et al., Dipeptidyl peptidase IV (DPP IV/CD26) is a cell-surface plasminogen receptor. Frontiers in Bioscience, 2008. 13: 1610-8.
  39. 39. Loster, K., et al., The cysteine-rich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site. Biochemical & Biophysical Research Communications, 1995. 217(1): 341-8.
  40. 40. Cheng, H.C., M. Abdel-Ghany, and B.U. Pauli, A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis. Journal of Biological Chemistry, 2003. 278(27): 24600-7.
  41. 41. Lee, K.N., et al., A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. Blood, 2004. 103(10): 3783-8.
  42. 42. Lee, K.N., et al., Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood, 2006. 107(4): 1397-404.
  43. 43. Milner, J.M., et al., Fibroblast activation protein alpha is expressed by chondrocytes following a pro-inflammatory stimulus and is elevated in osteoarthritis. Arthritis Res Ther, 2006. 8(1): R23.
  44. 44. Bauer, S., et al., Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther, 2006. 8(6): R171.
  45. 45. Levy, M.T., et al., Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology, 1999. 29(6): 1768-78.
  46. 46. Garinchesa, P., L.J. Old, and W.J. Rettig, Cell-Surface Glycoprotein of Reactive Stromal Fibroblasts as a Potential Antibody Target in Human Epithelial Cancers. Proceedings of the National Academy of Sciences of the United States of America, 1990. 87(18): 7235-7239.
  47. 47. Aoyama, A. and W.T. Chen, A 170-kDa membrane-bound protease is associated with the expression of invasiveness by human malignant melanoma cells. Proceedings of the National Academy of Sciences of the United States of America, 1990. 87(21): 8296-300.
  48. 48. Aertgeerts, K., et al., Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J Biol Chem, 2005. 280(20): 19441-4.
  49. 49. Ghersi, G., et al., Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J Biol Chem, 2002. 277(32): 29231-41.
  50. 50. Ghersi, G., et al., The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices. Cancer Research, 2006. 66(9): 4652-4661.
  51. 51. Ajami, K., et al., Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta, 2004. 1679(1): 18-28.
  52. 52. Yu, D.M., et al., The in vivo expression of dipeptidyl peptidases 8 and 9. J Histochem Cytochem, 2009. 57(11): 1025-40.
  53. 53. Pitman, M.R., et al., Dipeptidyl peptidase 8 and 9--guilty by association? Front Biosci, 2009. 14: 3619-33.
  54. 54. Geiss-Friedlander, R., et al., The cytoplasmic peptidase DPP9 is rate-limiting for degradation of proline-containing peptides. J Biol Chem, 2009. 284(40): 27211-9.
  55. 55. Yu, D.M., et al., Extraenzymatic functions of the dipeptidyl peptidase IV-related proteins DP8 and DP9 in cell adhesion, migration and apoptosis. FEBS Journal, 2006. 273(11): 2447-60.
  56. 56. Yao, T.W., et al., A novel role of dipeptidyl peptidase 9 in epidermal growth factor signaling. Mol Cancer Res, 2011. 9(7): 948-59.
  57. 57. Maes, M.B., et al., Dipeptidyl peptidase 8/9-like activity in human leukocytes. Journal of Leukocyte Biology, 2007. 81(5): 1252-1257.
  58. 58. Andersen, K.J. and J.K. McDonald, Lysosomal heterogeneity of dipeptidyl peptidase II active on collagen-related peptides. Ren Physiol Biochem, 1989. 12(1): 32-40.
  59. 59. McDonald, J.K. and C. Schwabe, Dipeptidyl peptidase II of bovine dental pulp. Initial demonstration and characterization as a fibroblastic, lysosomal peptidase of the serine class active on collagen-related peptides. Biochim Biophys Acta, 1980. 616(1): 68-81.
  60. 60. Mele, D.A., et al., Dipeptidyl peptidase 2 is an essential survival factor in the regulation of cell quiescence. Cell Cycle, 2009. 8(15): 2425-34.
  61. 61. Bista, P., et al., Lymphocyte quiescence factor Dpp2 is transcriptionally activated by KLF2 and TOB1. Mol Immunol, 2008. 45(13): 3618-23.
  62. 62. Danilova, O.V., et al., Neurogenin 3-specific dipeptidyl peptidase-2 deficiency causes impaired glucose tolerance, insulin resistance, and visceral obesity. Endocrinology, 2009. 150(12): 5240-8.
  63. 63. Mele, D.A., J.F. Sampson, and B.T. Huber, Th17 differentiation is the default program for DPP2-deficient T-cell differentiation. Eur J Immunol, 2011. 41(6): 1583-93.
  64. 64. Chiravuri, M., et al., A novel apoptotic pathway in quiescent lymphocytes identified by inhibition of a post-proline cleaving aminodipeptidase: a candidate target protease, quiescent cell proline dipeptidase. J Immunol, 1999. 163(6): 3092-9.
  65. 65. Underwood, R., et al., Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase. J Biol Chem, 1999. 274(48): 34053-8.
  66. 66. Wada, K., et al., Differential expression of two distinct forms of mRNA encoding members of a dipeptidyl aminopeptidase family. Proc Natl Acad Sci U S A, 1992. 89(1): 197-201.
  67. 67. Qi, S.Y., et al., Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases. Biochem J, 2003. 373(Pt 1): 179-89.
  68. 68. Jerng, H.H., A.D. Lauver, and P.J. Pfaffinger, DPP10 splice variants are localized in distinct neuronal populations and act to differentially regulate the inactivation properties of Kv4-based ion channels. Mol Cell Neurosci, 2007. 35(4): 604-24.
  69. 69. Du, J., et al., Expression of Dpp6 in mouse embryonic craniofacial development. Acta Histochem, 2011. 113(6): 636-9.
  70. 70. van Es, M.A., et al., Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis. Nat Genet, 2008. 40(1): 29-31.
  71. 71. Jones, S., et al., Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science, 2008. 321(5897): 1801-6.
  72. 72. Low, S.K., et al., Genome-wide association study of pancreatic cancer in Japanese population. PLoS One, 2010. 5(7): e11824.
  73. 73. Mentlein, R., Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regulatory Peptides, 1999. 85(1): 9-24.
  74. 74. Busek, P., R. Malik, and A. Sedo, Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. International Journal of Biochemistry & Cell Biology, 2004. 36(3): 408-21.
  75. 75. Sedo, A., et al., Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis? Arthritis Research & Therapy, 2005. 7(6): 253-69.
  76. 76. Jeffery, C.J., Moonlighting proteins: old proteins learning new tricks. Trends Genet, 2003. 19(8): 415-7.
  77. 77. Bjelke, J.R., et al., Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV. Biochemical Journal, 2006. 396(2): 391-9.
  78. 78. Ajami, K., et al., Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8. FEBS Lett, 2008. 582(5): 819-25.
  79. 79. Keane, F.M., et al., Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-alpha. FEBS J, 2011. 278(8): 1316-32.
  80. 80. Cordero, O.J., F.J. Salgado, and M. Nogueira, On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother, 2009. 58(11): 1723-47.
  81. 81. Gomez, N., et al., Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail, 2012. 14(1): 14-21.
  82. 82. Brandt, I., et al., Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem, 2006. 52(1): 82-7.
  83. 83. Marchetti, C., et al., High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV. Diabetologia, 2012. 55(1): 236-44.
  84. 84. de Meester, I., et al., Dipeptidyl peptidase IV substrates. An update on in vitro peptide hydrolysis by human DPPIV. Advances in Experimental Medicine & Biology, 2003. 524: 3-17.
  85. 85. Tagore, D.M., et al., Peptidase substrates via global peptide profiling. Nat Chem Biol, 2009. 5(1): 23-5.
  86. 86. Huang, C.H., et al., Cleavage-site specificity of prolyl endopeptidase FAP investigated with a full-length protein substrate. J Biochem, 2011. 149(6): 685-92.
  87. 87. Stremenova, J., et al., Expression and enzymatic activity of dipeptidyl peptidase-IV in human astrocytic tumours are associated with tumour grade. International Journal of Oncology, 2007. 31(4): 785-92.
  88. 88. Sedo, A., et al., Dipeptidyl peptidase-IV and related molecules: markers of malignancy? Expert Opinion on Medical Diagnostics, 2008. 2: 677-689.
  89. 89. Havre, P.A., et al., The role of CD26/dipeptidyl peptidase IV in cancer. Frontiers in Bioscience, 2008. 13: 1634-45.
  90. 90. Sato, T., et al., CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299. Cancer Research, 2005. 65(15): 6950-6.
  91. 91. Aytac, U. and N.H. Dang, CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy. Current Drug Targets - Immune Endocrine & Metabolic Disorders, 2004. 4(1): 11-8.
  92. 92. Cro, L., et al., CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL. Hematol Oncol, 2009. 27(3): 140-7.
  93. 93. Hirai, K., et al., Dipeptidyl peptidase IV (DPP IV/CD26) staining predicts distant metastasis of 'benign' thyroid tumor. Pathology International, 1999. 49(3): 264-265.
  94. 94. Yamaguchi, U., et al., Distinct gene expression-defined classes of gastrointestinal stromal tumor. J Clin Oncol, 2008. 26(25): 4100-8.
  95. 95. Pang, R., et al., A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell, 2010. 6(6): 603-15.
  96. 96. Amatya, V.J., et al., Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines. Oncol Rep, 2011. 26(6): 1369-75.
  97. 97. Inamoto, T., et al., Humanized Anti-CD26 Monoclonal Antibody as a Treatment for Malignant Mesothelioma Tumors. Clin Cancer Res, 2007. 13(14): 4191-4200.
  98. 98. Lu, C., et al., Dipeptidyl peptidases as survival factors in Ewing sarcoma family of tumors: implications for tumor biology and therapy. J Biol Chem, 2011. 286(31): 27494-505.
  99. 99. Wesley, U.V., et al., A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. Journal of Experimental Medicine, 1999. 190(3): 311-322.
  100. 100. Houghton, A.N., et al., Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation. Journal of Experimental Medicine, 1988. 167(1): 197-212.
  101. 101. Roesch, A., et al., Loss of dipeptidyl peptidase IV immunostaining discriminates malignant melanomas from deep penetrating nevi. Modern Pathology, 2006. 19(10): 1378-85.
  102. 102. Pethiyagoda, C.L., D.R. Welch, and T.P. Fleming, Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells. Clinical & Experimental Metastasis, 2000. 18(5): 391-400.
  103. 103. Arscott, W.T., et al., Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation. Oncogene, 2009. 28(4): 479-91.
  104. 104. Wesley, U.V., M. McGroarty, and A. Homoyouni, Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Research, 2005. 65(4): 1325-34.
  105. 105. Wesley, U.V., S. Tiwari, and A.N. Houghton, Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. International Journal of Cancer, 2004. 109(6): 855-66.
  106. 106. Wilson, M.J., et al., Dipeptidylpeptidase IV activities are elevated in prostate cancers and adjacent benign hyperplastic glands. Journal of Andrology, 2000. 21(2): 220-226.
  107. 107. Wilson, M.J., et al., Elevation of dipeptidylpeptidase iv activities in the prostate peripheral zone and prostatic secretions of men with prostate cancer: possible prostate cancer disease marker. Journal of Urology, 2005. 174(3): 1124-8.
  108. 108. Sedo, A., E. Krepela, and E. Kasafirek, Dipeptidyl peptidase IV, prolyl endopeptidase and cathepsin B activities in primary human lung tumors and lung parenchyma. Journal of Cancer Research & Clinical Oncology, 1991. 117(3): 249-53.
  109. 109. Asada, Y., et al., Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma. Histopathology, 1993. 23(3): 265-70.
  110. 110. McIntosh, C.H., Dipeptidyl peptidase IV inhibitors and diabetes therapy. Frontiers in Bioscience, 2008. 13: 1753-73.
  111. 111. Herman, G.A., et al., Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab, 2006. 91(11): 4612-9.
  112. 112. Masur, K., et al., DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells. Regulatory Peptides, 2006. 137(3): 147-55.
  113. 113. Sun, Y.X., et al., CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12. Clin Exp Metastasis, 2008. 25(7): 765-76.
  114. 114. Kajiyama, H., et al., Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. Cancer Research, 2003. 63(9): 2278-83.
  115. 115. Kajiyama, H., et al., Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma. Cancer Research, 2002. 62(10): 2753-7.
  116. 116. Kajiyama, H., et al., The expression of dipeptidyl peptidase IV (DPPIV/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells. Cancer Sci, 2010. 101(2): 347-54.
  117. 117. Gonzalez-Gronow, M., et al., Angiostatin directly inhibits human prostate tumor cell invasion by blocking plasminogen binding to its cellular receptor, CD26. Experimental Cell Research, 2005. 303(1): 22-31.
  118. 118. Busek, P., et al., Dipeptidyl peptidase-IV inhibits glioma cell growth independent of its enzymatic activity. Int J Biochem Cell Biol, 2012. 44(5): 738-47.
  119. 119. Goldstein, L.A., et al., Molecular cloning of seprase: a serine integral membrane protease from human melanoma. Biochimica et Biophysica Acta, 1997. 1361(1): 11-9.
  120. 120. Gilmore, B.F., et al., Dipeptide proline diphenyl phosphonates are potent, irreversible inhibitors of seprase (FAPalpha). Biochemical & Biophysical Research Communications, 2006. 346(2): 436-46.
  121. 121. Artym, V.V., et al., Molecular proximity of seprase and the urokinase-type plasminogen activator receptor on malignant melanoma cell membranes: dependence on beta1 integrins and the cytoskeleton. Carcinogenesis, 2002. 23(10): 1593-601.
  122. 122. Monsky, W.L., et al., A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. Cancer Research, 1994. 54(21): 5702-10.
  123. 123. Ramirez-Montagut, T., et al., FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor. Oncogene, 2004. 23(32): 5435-46.
  124. 124. Rettig, W.J., et al., Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Research, 1993. 53(14): 3327-35.
  125. 125. Kelly, T., et al., Seprase, a membrane-bound protease, is overexpressed by invasive ductal carcinoma cells of human breast cancers. Modern Pathology, 1998. 11(9): 855-63.
  126. 126. Goodman, J.D., T.L. Rozypal, and T. Kelly, Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells. Clinical & Experimental Metastasis, 2003. 20(5): 459-70.
  127. 127. Huang, Y., S. Wang, and T. Kelly, Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res, 2004. 64(8): 2712-6.
  128. 128. Huang, Y., et al., Fibroblast activation protein-alpha promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions. Clin Exp Metastasis, 2011. 28(6): 567-79.
  129. 129. Dohi, O., et al., Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours. Histopathology, 2009. 55(4): 432-40.
  130. 130. Mori, Y., et al., The expression of a type II transmembrane serine protease (Seprase) in human gastric carcinoma. Oncology, 2004. 67(5-6): 411-9.
  131. 131. Goscinski, M.A., et al., Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China. Oncology, 2008. 75(1-2): 49-59.
  132. 132. Iwasa, S., et al., Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer.[erratum appears in Cancer Lett. 2005 Sep 28;227(2):227][republished in Cancer Lett. 2005 Sep 28;227(2):229-36; PMID: 16196122]. Cancer Letters, 2003. 199(1): 91-8.
  133. 133. Jin, X., et al., Expression patterns of seprase, a membrane serine protease, in cervical carcinoma and cervical intraepithelial neoplasm.[erratum appears in Anticancer Res. 2003;23:5371-2]. Anticancer Research, 2003. 23(4): 3195-8.
  134. 134. Wilson, C.H. and C.A. Abbott, Expression profiling of dipeptidyl peptidase 8 and 9 in breast and ovarian carcinoma cell lines. Int J Oncol, 2012. 41(3): 919-32.
  135. 135. Sulda, M.L., et al., Expression and prognostic assessment of dipeptidyl peptidase IV and related enzymes in B-cell chronic lymphocytic leukemia. Cancer Biol Ther, 2010. 10(2): 180-9.
  136. 136. Klener, P., et al., Possible Prognostic-Significance of the Assessment of Dipeptidylpeptidase-Ii in Peripheral-Blood Lymphocytes of Patients with Chronic Lymphocytic-Leukemia. Neoplasma, 1987. 34(5): 581-586.
  137. 137. Danilov, A.V., et al., Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia. Exp Hematol, 2010. 38(12): 1167-77.
  138. 138. Pure, E., The road to integrative cancer therapies: emergence of a tumor-associated fibroblast protease as a potential therapeutic target in cancer. Expert Opin Ther Targets, 2009. 13(8): 967-73.
  139. 139. Takasawa, W., et al., Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines. Biochem Biophys Res Commun, 2010. 401(1): 7-12.
  140. 140. Matheeussen, V., et al., Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol Chem, 2011. 392(3): 189-98.
  141. 141. Arwert, E.N., et al., Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation. Oncogene, 2011. 31(8): 992-1000.
  142. 142. Shin, J.W., G. Jurisic, and M. Detmar, Lymphatic-specific expression of dipeptidyl peptidase IV and its dual role in lymphatic endothelial function. Exp Cell Res, 2008. 314(16): 3048-56.
  143. 143. Cheng, H.C., et al., Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin. Journal of Biological Chemistry, 1998. 273(37): 24207-15.
  144. 144. Ghersi, G., et al., Critical role of dipeptidyl peptidase IV in neuropeptide Y-mediated endothelial cell migration in response to wounding. Peptides, 2001. 22(3): 453-8.
  145. 145. Aimes, R.T., et al., Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis. Thromb Haemost, 2003. 89(3): 561-72.
  146. 146. Ghilardi, C., et al., Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics, 2008. 9: 201.
  147. 147. Kidd, S., et al., Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One, 2012. 7(2): e30563.
  148. 148. Atherton, A.J., et al., Dipeptidyl peptidase IV expression identifies a functional sub-population of breast fibroblasts. Int J Cancer, 1992. 50(1): 15-9.
  149. 149. Atherton, A.J., et al., Ectoenzyme regulation by phenotypically distinct fibroblast sub-populations isolated from the human mammary gland. J Cell Sci, 1994. 107 ( Pt 10): 2931-9.
  150. 150. Moehrle, M.C., et al., Aminopeptidase-M and Dipeptidyl Peptidase-Iv Activity in Epithelial Skin Tumors - a Histochemical-Study. Journal of Cutaneous Pathology, 1995. 22(3): 241-247.
  151. 151. Kacar, A., et al., Stromal expression of CD34, alpha-smooth muscle actin and CD26/DPPIV in squamous cell carcinoma of the skin: a comparative immunohistochemical study. Pathol Oncol Res, 2012. 18(1): 25-31.
  152. 152. Park, J.E., et al., Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. Journal of Biological Chemistry, 1999. 274(51): 36505-12.
  153. 153. O'Brien, P. and B.F. O'Connor, Seprase: An overview of an important matrix serine protease. Biochimica Biophysica Acta, 2008. 1784(9):1130-45.
  154. 154. Rettig, W.J., et al., Fibroblast activation protein: purification, epitope mapping and induction by growth factors. International Journal of Cancer, 1994. 58(3): 385-92.
  155. 155. Waster, P., et al., Ultraviolet exposure of melanoma cells induces fibroblast activation protein-alpha in fibroblasts: Implications for melanoma invasion. Int J Oncol, 2011.
  156. 156. Zhang, J., M. Valianou, and J.D. Cheng, Identification and characterization of the promoter of fibroblast activation protein. Front Biosci (Elite Ed), 2010. 2: 1154-63.
  157. 157. Christiansen, V.J., et al., Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV. Arch Biochem Biophys, 2007. 457(2): 177-86.
  158. 158. Lee, H.O., et al., FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer, 2011. 11: 245.
  159. 159. Santos, A.M., et al., Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest, 2009. 119(12): 3613-25.
  160. 160. Kraman, M., et al., Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science, 2010. 330(6005): 827-30.
  161. 161. Ge, Y., et al., Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. British Journal of Haematology, 2006. 133(1): 83-92.
  162. 162. Cohen, S.J., et al., Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas, 2008. 37(2): 154-8.
  163. 163. Saadi, A., et al., Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci U S A. 107(5): 2177-82.
  164. 164. Ariga, N., et al., Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int J Cancer, 2001. 95(1): 67-72.
  165. 165. Balaziova, E., et al., Dipeptidyl peptidase-IV activity and/or structure homologs (DASH): contributing factors in the pathogenesis of rheumatic diseases? Advances in Experimental Medicine & Biology, 2006. 575: 169-74.
  166. 166. Bank, U., et al., Outside or inside: role of the subcellular localization of DP4-like enzymes for substrate conversion and inhibitor effects. Biol Chem, 2011. 392(3): 169-87.
  167. 167. Uematsu, T., et al., Effects of oral squamous cell carcinoma-derived TGF-beta1 on CD26/DPPIV expression in T cells. Anticancer Research, 2004. 24(2B): 619-24.
  168. 168. Adams, S., et al., PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Research, 2004. 64(15): 5471-80.
  169. 169. Sulda, M.L., C.A. Abbott, and M. Hildebrandt, DPIV/CD26 and FAP in cancer: a tale of contradictions. Advances in Experimental Medicine & Biology, 2006. 575: 197-206.
  170. 170. Medeiros Mdos, S., et al., Hydrolysis of atrial and brain natriuretic peptides by the human astrocytoma clone D384 and the neuroblastoma line SH-SY5Y. Neuroendocrinology, 1991. 54(3): 295-302.
  171. 171. Sedo, A., et al., Dipeptidyl peptidase IV in two human glioma cell lines. European Journal of Histochemistry, 2001. 45(1): 57-63.
  172. 172. Sedo, A., R. Malik, and E. Krepela, Dipeptidyl peptidase IV in C6 rat glioma cell line differentiation. Biological Chemistry, 1998. 379(1): 39-44.
  173. 173. Sedo, A. and R.P. Revoltella, Detection of dipeptidyl peptidase IV in glioma C6 and neuroblastoma SK-N-SH cell lines. Biochemistry & Cell Biology, 1995. 73(1-2): 113-5.
  174. 174. Malik, R., et al., Dipeptidyl peptidase-IV activity and/or structure homologues (DASH) in transformed neuroectodermal cells. Advances in Experimental Medicine & Biology, 2003. 524: 95-102.
  175. 175. Busek, P., J. Stremenova, and A. Sedo, Dipeptidyl peptidase-IV enzymatic activity bearing molecules in human brain tumors-good or evil? Frontiers in Bioscience, 2008. 13: 2319-26.
  176. 176. Mentlein, R., et al., Expression and role of the cell surface protease seprase/fibroblast activation protein-alpha (FAP-alpha) in astroglial tumors. Biol Chem, 2011.
  177. 177. Rettig, W.J., et al., Differential expression of cell surface antigens and glial fibrillary acidic protein in human astrocytoma subsets. Cancer Research, 1986. 46(12 Pt 1): 6406-12.
  178. 178. Balaziova, E., et al., Coupled expression of dipeptidyl peptidase-IV and fibroblast activation protein-alpha in transformed astrocytic cells. Mol Cell Biochem, 2011. 354(1-2): 283-9.
  179. 179. Paulus, W., C. Huettner, and J.C. Tonn, Collagens, integrins and the mesenchymal drift in glioblastomas: a comparison of biopsy specimens, spheroid and early monolayer cultures. Int J Cancer, 1994. 58(6): 841-6.
  180. 180. Li, J., et al., An Activatable Near Infrared Fluorescent Probe for In Vivo Imaging of Fibroblast Activation Protein-alpha. Bioconjug Chem, 2012. 23: 1704-1711.
  181. 181. Lojda, Z., Proteinases in pathology. Usefulness of histochemical methods. J Histochem Cytochem, 1981. 29(3A Suppl): 481-93.
  182. 182. Guieu, R., et al., CD26 modulates nociception in mice via its dipeptidyl-peptidase IV activity. Behavioural Brain Research, 2006. 166(2): 230-5.
  183. 183. Sakurada, C., et al., Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptidyl peptidase IV: an in vitro and in vivo study. Biochemical Pharmacology, 2003. 66(4): 653-61.
  184. 184. Karl, T., et al., Extreme reduction of dipeptidyl peptidase IV activity in F344 rat substrains is associated with various behavioral differences. Physiology & Behavior, 2003. 80(1): 123-34.
  185. 185. Rohnert, P., et al., Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia. J Neuroinflammation, 2012. 9: 44.
  186. 186. Mentlein, R. and G. Struckhoff, Purification of two dipeptidyl aminopeptidases II from rat brain and their action on proline-containing neuropeptides. Journal of Neurochemistry, 1989. 52(4): 1284-93.
  187. 187. Frerker, N., et al., Neuropeptide Y (NPY) cleaving enzymes: structural and functional homologues of dipeptidyl peptidase 4. Peptides, 2007. 28(2): 257-68.
  188. 188. Gorenstein, C., V.T. Tran, and S.H. Snyder, Brain peptidase with a unique neuronal localization: the histochemical distribution of dipeptidyl-aminopeptidase II. Journal of Neuroscience, 1981. 1(10): 1096-102.
  189. 189. Stevens, B.R., et al., Dipeptidyl peptidase-II activity in cultured astroglial cells from neonatal rat brain. Brain Research, 1987. 406(1-2): 113-7.
  190. 190. Struckhoff, G., Dipeptidyl peptidase II in astrocytes of the rat brain. Meningeal cells increase enzymic activity in cultivated astrocytes. Brain Research, 1993. 620(1): 49-57.
  191. 191. Mares, V., et al., Compartment- and malignance-dependent up-regulation of gamma-glutamyltranspeptidase and dipetidylpeptidase-IV activity in human brain gliomas. Histol Histopathol, 2012. 27(7): 931-40.
  192. 192. Network, C.G.A.R., Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 2008. 455(7216): 1061-8.
  193. 193. Mikheeva, S.A., et al., TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Mol Cancer, 2010. 9: 194.
  194. 194. Huse, J.T., H.S. Phillips, and C.W. Brennan, Molecular subclassification of diffuse gliomas: seeing order in the chaos. Glia, 2011. 59(8): 1190-9.
  195. 195. Verhaak, R.G., et al., Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 2010. 17(1): 98-110.
  196. 196. Venere, M., et al., Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. Glia, 2011. 59(8): 1148-54.
  197. 197. Bonavia, R., et al., Heterogeneity maintenance in glioblastoma: a social network. Cancer Res, 2011. 71(12): 4055-60.
  198. 198. Charles, N.A., et al., The brain tumor microenvironment. Glia, 2012. 59(8): 1169-80.
  199. 199. Kouno, J., et al., Up-regulation of CC chemokine, CCL3L1, and receptors, CCR3, CCR5 in human glioblastoma that promotes cell growth. Journal of Neuro-Oncology, 2004. 70(3): 301-7.
  200. 200. Pham, K., et al., CCL5, CCR1 and CCR5 in murine glioblastoma: immune cell infiltration and survival rates are not dependent on individual expression of either CCR1 or CCR5. J Neuroimmunol, 2012. 246(1-2): 10-7.
  201. 201. Soroceanu, L., et al., Human cytomegalovirus US28 found in glioblastoma promotes an invasive and angiogenic phenotype. Cancer Res, 2011. 71(21): 6643-53.
  202. 202. Jacobs, J.F., et al., Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol, 2010. 225(1-2): 195-9.
  203. 203. Jordan, J.T., et al., Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother, 2008. 57(1): 123-31.
  204. 204. Sreekanthreddy, P., et al., Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev, 2010. 19(6): 1409-22.
  205. 205. Liu, C., et al., Chemokine receptor CXCR3 promotes growth of glioma. Carcinogenesis, 2011. 32(2): 129-37.
  206. 206. Maru, S.V., et al., Chemokine production and chemokine receptor expression by human glioma cells: role of CXCL10 in tumour cell proliferation. J Neuroimmunol, 2008. 199(1-2): 35-45.
  207. 207. Hattermann, K., et al., The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res, 2010. 70(8): 3299-308.
  208. 208. Calatozzolo, C., et al., Expression of the new CXCL12 receptor, CXCR7, in gliomas. Cancer Biol Ther, 2011. 11(2): 242-53.
  209. 209. Jiang, Z., et al., Contribution of SDF-1alpha/CXCR4 Signaling to Brain Development and Glioma Progression. Neurosignals, 2012.
  210. 210. Lazarczyk, M., E. Matyja, and A. Lipkowski, Substance P and its receptors -- a potential target for novel medicines in malignant brain tumour therapies (mini-review). Folia Neuropathol, 2007. 45(3): 99-107.
  211. 211. Palma, C. and C.A. Maggi, The role of tachykinins via NK1 receptors in progression of human gliomas. Life Sciences, 2000. 67(9): 985-1001.
  212. 212. Dufes, C., et al., Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro. J Mol Neurosci, 2003. 21(2): 91-102.
  213. 213. Sharma, A., et al., A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells. J Mol Neurosci, 2001. 17(3): 331-9.
  214. 214. Busek, P., et al., Modulation of substance P signaling by dipeptidyl peptidase-IV enzymatic activity in human glioma cell lines. Physiological Research, 2008. 57(3): 443-9.
  215. 215. Kaur, B., et al., Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol, 2005. 7(2): 134-53.
  216. 216. Sato, Y., et al., Involvement of dipeptidyl peptidase IV in extravillous trophoblast invasion and differentiation. J Clin Endocrinol Metab, 2002. 87(9): 4287-96.
  217. 217. Dang, D.T., et al., Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition. Cancer Res, 2008. 68(6): 1872-80.
  218. 218. Lee, E.W., et al., Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. Journal of Clinical Investigation, 2003. 111(12): 1853-62.
  219. 219. Tilan, J., et al., Differential functions of neuropeptide Y in Ewing's sarcoma - hypoxia as a switch Cancer Research Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR, 2012. 72(8 Suppl:Abstract nr 3950).
  220. 220. Lal, A., et al., Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res, 2002. 62(12): 3335-9.
  221. 221. Fukushima, T. and H. Kataoka, Roles of insulin-like growth factor binding protein-2 (IGFBP-2) in glioblastoma. Anticancer Res, 2007. 27(6A): 3685-92.
  222. 222. Wang, H., et al., Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res, 2003. 63(15): 4315-21.
  223. 223. Qin, Q., et al., Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. Cell Res, 2012. 22(1): 90-106.
  224. 224. Bellail, A.C., et al., Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol, 2004. 36(6): 1046-69.
  225. 225. Viapiano, M.S., S.E. Lawler, and E.G. Meir, Glioma Invasion: Mechanisms and Therapeutic Challenges. CNS Cancer, B.A. Teicher, Editor. 2009, Humana Press. 1219-1252.
  226. 226. Mueller, S.C., et al., A novel protease-docking function of integrin at invadopodia. Journal of Biological Chemistry, 1999. 274(35): 24947-52.
  227. 227. Gondi, C.S., et al., Expression of seprase on the cellular surface is dependent on uPAR and cathepsin B expression levels in gliomas. AACR Meeting Abstracts, 2006. 2006(1): 389-d-390.
  228. 228. Zukowska-Grojec, Z., et al., Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circulation Research, 1998. 83(2): 187-95.
  229. 229. Brat, D.J. and E.G. Van Meir, Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest, 2004. 84(4): 397-405.
  230. 230. Rong, Y., et al., 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol, 2006. 65(6): 529-39.
  231. 231. Rong, Y., D.J. Brat, and E.G. Meir, Vaso-occlusive Mechanisms that Intiate Hypoxia and Necrosis in Glioblastoma: The Role of Thrombosis and Tissue Factor. CNS Cancer, B.A. Teicher, Editor. 2009, Humana Press. 507-528.
  232. 232. Lee, K.N., et al., Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor alpha2-antiplasmin. J Thromb Haemost, 2011. 9(5): 987-96.
  233. 233. Aratake, Y., et al., Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules. Diagnostic Cytopathology, 2002. 26(6): 366-372.
  234. 234. Shaw, E.J., et al., Gene expression in oligodendroglial tumors. Anal Cell Pathol (Amst), 2010. 33(2): 81-94.
  235. 235. Inamoto, T., et al., Anti-CD26 Monoclonal Antibody-Mediated G1-S Arrest of Human Renal Clear Cell Carcinoma Caki-2 Is Associated with Retinoblastoma Substrate Dephosphorylation, Cyclin-Dependent Kinase 2 Reduction, p27kip1 Enhancement, and Disruption of Binding to the Extracellular Matrix. Clin Cancer Res, 2006. 12(11): 3470-3477.
  236. 236. Ho, L., et al., In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clin Cancer Res, 2001. 7(7): 2031-40.
  237. 237. Messerschmidt, S.K., et al., Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells. J Control Release, 2009. 137(1): 69-77.
  238. 238. Muller, D., K. Frey, and R.E. Kontermann, A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy. J Immunother, 2008. 31(8): 714-22.
  239. 239. Liao, D., et al., Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One, 2009. 4(11): e7965.
  240. 240. Loeffler, M., et al., Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. Journal of Clinical Investigation, 2006. 116(7): 1955-62.
  241. 241. Lee, J., et al., Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Research, 2005. 65(23): 11156-63.
  242. 242. Fassnacht, M., et al., Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. Clinical Cancer Research, 2005. 11(15): 5566-71.
  243. 243. Lebeau, A.M., et al., Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Mol Cancer Ther, 2009. 8(5):1378-86.
  244. 244. Neumiller, J.J., L. Wood, and R.K. Campbell, Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy, 2010. 30(5): 463-84.
  245. 245. Vanhoof, G., et al., Proline motifs in peptides and their biological processing. FASEB Journal, 1995. 9(9): 736-44.
  246. 246. Bernstein, H.G., et al., Immunolocalization of dipeptidyl aminopeptidase (DAP IV) in the developing human brain. International Journal of Developmental Neuroscience, 1987. 5(3): 237-42.
  247. 247. Tatenhorst, L., et al., Regulators of G-protein signaling 3 and 4 (RGS3, RGS4) are associated with glioma cell motility. J Neuropathol Exp Neurol, 2004. 63(3): 210-22.
  248. 248. Van Meir, E.G., et al., Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin, 2010. 60(3): 166-93.
  249. 249. Jones, T.S. and E.C. Holland, Standard of care therapy for malignant glioma and its effect on tumor and stromal cells. Oncogene, 2012. 31(16): 1995-2006.

Written By

Petr Busek and Aleksi Sedo

Submitted: 28 April 2012 Published: 27 February 2013